What 12 Analyst Ratings Have To Say About Bristol-Myers Squibb
Portfolio Pulse from Benzinga Insights
In the last quarter, Bristol-Myers Squibb (NYSE:BMY) received various analyst ratings. The 12 analysts have an average price target of $72.58, compared to the current price of $56.48, implying an upside. However, this average represents a 4.98% decrease from the previous average price target of $76.38.
October 20, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol-Myers Squibb received mixed analyst ratings, with an average price target of $72.58, implying an upside from the current price. However, this is a decrease from the previous average target.
The mixed analyst ratings indicate uncertainty about the company's performance. While the average price target suggests an upside, the decrease from the previous target may impact investor sentiment and potentially the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100